P
Pierre Amarenco
Researcher at University of Paris
Publications - 431
Citations - 40040
Pierre Amarenco is an academic researcher from University of Paris. The author has contributed to research in topics: Stroke & Myocardial infarction. The author has an hindex of 97, co-authored 415 publications receiving 35259 citations. Previous affiliations of Pierre Amarenco include Claude Bernard University Lyon 1 & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco,Julien Bogousslavsky,Callahan A rd,Larry B. Goldstein,M.G. Hennerici,Amy E. Rudolph,Henrik Sillesen,Lisa Simunovic,Michael Szarek,K M Welch,Justin A. Zivin,Stroke Prevention by Aggressive Reduction in Cholesterol Levels (Sparcl) Investigators +11 more
TL;DR: In this paper, the authors showed that 80 mg of atorvastatin per day reduced the overall incidence of stroke and cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke.
Journal ArticleDOI
Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006.
Pierre-Jean Touboul,M.G. Hennerici,Stephen Meairs,Harold P. Adams,Pierre Amarenco,N. M. Bornstein,László Csiba,M. Desvarieux,Shah Ebrahim,Marc Fatar,R. Hernandez Hernandez,Michael R. Jaff,S. Kownator,Patrizio Prati,Tatjana Rundek,Matthias Sitzer,Ulf Schminke,J.-C. Tardif,A. Taylor,Eric Vicaut,K.S. Woo,Faiez Zannad,Mahmoud Zureik +22 more
TL;DR: Although IMT has been suggested to represent an important risk marker, according to the current evidence it does not fulfill the characteristics of an accepted risk factor and will help to improve the power of randomized clinical trials incorporating IMT measurements and to facilitate the merging of large databases for meta-analyses.
Journal ArticleDOI
Lipoprotein(a) as a cardiovascular risk factor: current status
Børge G. Nordestgaard,M. John Chapman,Kausik K. Ray,Jan Borén,Felicita Andreotti,Gerald F. Watts,Henry N. Ginsberg,Pierre Amarenco,Alberico L. Catapano,Olivier S. Descamps,Edward A. Fisher,Petri T. Kovanen,Jan Albert Kuivenhoven,Philippe Lesnik,Luis Masana,Zeljko Reiner,Marja-Riitta Taskinen,Lale Tokgozoglu,Anne Tybjærg-Hansen +18 more
TL;DR: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated LP(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD.
Journal ArticleDOI
Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004-2006-2011). An Update on Behalf of the Advisory Board of the 3rd, 4th and 5th Watching the Risk Symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011.
Pierre-Jean Touboul,M.G. Hennerici,Stephen Meairs,Harold P. Adams,Pierre Amarenco,N. M. Bornstein,László Csiba,M. Desvarieux,Shah Ebrahim,R. Hernandez Hernandez,Michael R. Jaff,S. Kownator,Tasneem Z. Naqvi,Patrizio Prati,Tatjana Rundek,Matthias Sitzer,Ulf Schminke,J.-C. Tardif,A. Taylor,Eric Vicaut,K.S. Woo +20 more
TL;DR: This updated consensus document delineates further criteria to distinguish early atherosclerotic plaque formation from thickening of IMT and recommends against serial monitoring in individual patients.
Journal ArticleDOI
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman,Henry N. Ginsberg,Pierre Amarenco,Felicita Andreotti,Jan Borén,Alberico L. Catapano,Olivier S. Descamps,Edward A. Fisher,Petri T. Kovanen,Jan Albert Kuivenhoven,Philippe Lesnik,Luis Masana,Børge G. Nordestgaard,Kausik K. Ray,Zeljko Reiner,Marja-Riitta Taskinen,Lale Tokgozoglu,Anne Tybjærg-Hansen,Gerald F. Watts +18 more
TL;DR: Recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal, and that therapeutic targeting of elevated triglycerides, a marker of TRL and their remnants, and/or low HDL-C may provide further benefit.